| [1] |
Bria E, Nistico C, Cuppone F, et al. Benefit of taxanes as adjuvant chemotherapy,for early breast cancer: pooled analysis of 15 500 patients[J]. Cancer, 2006, 106(11):2337-2344.
|
| [2] |
姚清深,秦军,陈春媚,等. 乳腺癌的TECIA 法药敏试验及其临床应用价值[J/CD]. 中华乳腺病杂志:电子版,2009 ,3(3):288-293.
|
| [3] |
Mamounas EP, Bryant J, Lembersky BC, et al. Paclitaxel after doxorubicin plus cyclophosphamide as adjuvant chemotherapy for node-positive breast cancer: Results from NSABP-B 28[J]. J Clin Oncol, 2005, 23(16):3686-3696.
|
| [4] |
Rouzier R, Rajan R, Wagner P, et al. Microtubule-associated protein Tau: a marker of paclitaxel sensitivity in breast cancer[J]. Proc Natl Acad Sci USA,2005, 102(23):8315-8320.
|
| [5] |
Mimori K, Sadanaga N, Yoshikawa Y, et al. Reduced Tau expression in gastric cancer can identify candidates for successful Paclitaxel treatment[J]. Br J Cancer,2006,94(12):1894-1897.
|
| [6] |
Jimeno A, Hallur G, Chan A, et al. Development of two novel benzoylphenylurea sulfur analogues and evidence that the microtubule-associated protein Tau is predictive of their activity in pancreatic cancer[J]. Mol Cancer Ther,2007,6(5):1509-1516.
|
| [7] |
Andreadis A, Brown WM, Kosik KS. Structure and novel exons of the human Tau gene[J]. Biochemistry, 1992, 31(43):10 626-10 633.
|
| [8] |
Goode BL, Chau M, Denis PE, et al. Structural and functional differences between 3-repeat and 4-repeat Tau isoforms:Implications for normal Tau function and the onset of neurodegenetative disease [ J]. J Biol Chem, 2000,275(49):38 182-38 189.
|
| [9] |
Mandelkow E, von Bergen M, Biernat J, et al. Structural principles of Tau and the paired helical filaments of Alzheimer’s disease[J]. Brain Pathol,2007,17(1): 83-90.
|
| [10] |
Rosenberg KJ, Ross JL, Feinstein HE, et al. Comple-mentary dimerization of microtubule-associated Tau protein:implications for microtubule bundling and Tau-mediated pathogenesis[J]. Proc Natl Acad Sci USA,2008,105(21):7445-7450.
|
| [11] |
Mazanetz MP, Fischer PM. Untangling Tau hyperphos-phorylation in drug design for neurodegenerative diseases[J]. Nat Rev Drug Discov,2007,6(6):464-479.
|
| [12] |
Shahani N, Brandt R. Functions and malfunctions of the Tau proteins[J]. Cell Mol Life Sci,2002,59(10):1668-1680.
|
| [13] |
Liu Y, Liu F, Iqbal K, et al. Decreased glucose trans-porters correlate to abnormal hyperphosphorylation of Tau in Alzheimer disease[J].FEBS Lett,2008,582(2): 359-364.
|
| [14] |
Deng Y, Li B, Liu F, et al. Regulation between O-GlcNA cylation and phosphorylation of neurofilament-M and their dysregulation in Alzheimer disease[J]. FASEB J,2008,22(1):138-145.
|
| [15] |
Goedert M. Tau gene mutations and their effects[J]. Mov Disord,2005,12:S45-S52.
|
| [16] |
Andre F, Hatzis C, Anderson K, et al. Microtubule associated protein-Tau is a bifunctional predictor of endocrine sensitivity and chemotherapy resistance in estrogen receptor positive breast cancer[J]. Clin Cancer Res,2007,13(7):2061-2067.
|
| [17] |
Ikeda H, Taira N, Hara F, et al. The estrogen receptor influences microtubule-associated protein Tau (MAPT) expression and the selective estrogen receptor inhibitor fulvestrant downregulates MAPT and increases the sensitivity to taxane in breast cancer cells[J]. Breast Cancer Res,2010,12(3):R43.
|
| [18] |
Andre F, Mazouni C, Liedtke C, et al. HER-2 expression and efficacy of preoperative paclitaxel/FAC chemotherapy in breast cancer[J]. Breast Cancer Res Treat,2008,108(2):183-190.
|
| [19] |
Pentheroudakis C, Kalogeras KT, Wirtz RM, et al. Gene expression of estrogen receptor, progesterone receptor and microtubule-associated protein Tau in high-risk early breast cancer a quest for molecular predictors[J]. Breast Cancer Res Treat, 2009,116(1):131-143.
|
| [20] |
Tanaka S, Nohara T, Iwamoto M, et al. Tau expression and efficacy of paclitaxel treatment in metastatic breast cancer[J].Cancer Chemother Pharmacol,2009,64(2):341-346.
|
| [21] |
Pusztai L, Jeong JH, Gong Y, et al. Evaluation of Micro-tubule-Associated Protein-Tau Expression As a Prognostic and Predictive Marker in the NSABP-B 28 Randomized Clinical Trial[J]. J Clin Oncol,2009,27(26):4287-4292.
|
| [22] |
Kar S, Fan J, Smith MJ, et al. Repeat motifs of Tau bind to the insides of microtubules in the absence of taxol[J]. EMBO J,2003,22(1):70-77.
|
| [23] |
Al-Bassam J, Ozer RS, Safer D, et al. MAP2 and Tau bind longitudinally along the outer ridges of microtubule protofilaments[J]. J Cell Biol,2002,157(7):1187-1196.
|
| [24] |
Makrides V, Masie MR, Feinstein SC, et al. Evidence for two distinct binding sites for Tau on microtubules[J]. Proc Natl Acad Sci USA,2004,101(17):6746-6751.
|
| [25] |
Wagner P, Wang B, Clark E, et al. Microtubule-associated protein (MAP)-Tau: a novel mediator of paclitaxel sensitivity in vitro and in vivo[J]. Cell Cycle,2005,4(9):1149-1152.
|
| [26] |
Hess KR, Anderson K, Symmans WF, et al. Pharmaco-genomic predictor of sensitivity to preoperative chemotherapy with paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide in breast cancer[J]. J Clin Oncol,2006,24(26):4236-4244.
|
| [27] |
Peintinger F, Anderson K, Mazouni C, et al. Thirty-gene pharmacogenomic test correlates with residual cancer burden after preoperative chemotherapy breast cancer[J]. Clin Cancer Res,2007,13(14):4078-4082.
|
| [28] |
Shao YY, Kuo KT, Hu FC, et al. Predictive and prognostic values of Tau and ERCC1 in advanced breast cancer patients treated with paclitaxel and cisplatin[J]. Jpn J Clin Oncol,2010,40(4):286-293.
|
| [29] |
Rody A, Karn T, Gätje R, et al. Gene expression profiling of breast cancer patients treated with docetaxel, doxorubicin, and cyclophosphamide within the GEPARTRIO trial HER-2, but not topoisomerase II alpha and microtubule-associated protein Tau, is highly predictive of tumor response[J]. Breast,2007,16(1):86-93.
|
| [30] |
Dumontet C, Krajewska M, Treilleux I, et al. BCIRG 001 molecular analysis: prognostic factors in node-positive breast cancer patients receiving adjuvant chemotherapy[J]. Clin Cancer Res,2010,16(15):3988-3997.
|